GlassScriptPhysician profile
Lindsay M Mcgehee
NPI 1932417151
$3,284.15
in general payments reported to CMS, 2019-2025
23 companies · $1,033 in 2025
The $1,033 reported for 2025 was more than what 87% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $64.74 · 2022: $44.00 · 2023: $1,155 · 2024: $987 · 2025: $1,033.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,175.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,175.41 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $528.14 | 2022-2025 | Airsupra, Farxiga, Breztri |
| Abbvie INC. | $519.45 | 2023-2025 | |
| Novo Nordisk INC | $445.22 | 2023-2025 | Ozempic, Wegovy, Rybelsus |
| Amgen INC. | $402.46 | 2023-2025 | Repatha, Otezla, Repatha |
| Boehringer Ingelheim Pharmaceuticals, INC. | $368.34 | 2023-2025 | Jardiance, Stiolto Respimat, Ofev |
| Pfizer INC. | $207.55 | 2023-2025 | |
| Lilly USA, LLC | $166.43 | 2023-2024 | Mounjaro, Jardiance, Zepbound |
| Radius Health, INC. | $99.80 | 2023-2025 | Tymlos |
| Genentech USA, INC. | $94.80 | 2021-2023 | Xofluza |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $58.17 | 2025 | Caplyta |
| Bayer Healthcare Pharmaceuticals INC. | $56.40 | 2023-2025 | |
| Lundbeck LLC | $54.92 | 2023-2025 | Vyepti |
| Dynavax Technologies Corporation | $54.67 | 2023-2024 | Heplisav-B |
| Glaxosmithkline, LLC. | $45.77 | 2023-2025 | Arexvy, Shingrix |
| Electromed, INC. | $31.66 | 2023 | Smartvest |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Phathom Pharmaceuticals, INC. | $28.54 | 2024-2025 | Voquezna |
| Abiomed | $22.19 | 2024 | Impella |
| Astellas Pharma US INC | $21.06 | 2023 | Veozah |
| Teva Pharmaceuticals USA, INC. | $16.72 | 2022 | |
| Pharming Healthcare, INC. | $16.32 | 2024 | Ruconest |
| Sumitomo Pharma America, INC. | $15.95 | 2023 | Gemtesa |
| Novartis Pharmaceuticals Corporation | $15.61 | 2023 | |
| Idorsia Pharmaceuticals US INC | $13.98 | 2024 | Quviviq |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lindsay Mcgehee listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.